Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have been given an average recommendation of “Moderate Buy” by the nine research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $21.1250.

Several brokerages have recently commented on TLX. Wall Street Zen downgraded Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday. Citigroup lifted their price target on Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers raised its stake in Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after purchasing an additional 1,392 shares during the period. XTX Topco Ltd purchased a new position in shares of Telix Pharmaceuticals during the fourth quarter valued at $89,000. IHT Wealth Management LLC acquired a new position in Telix Pharmaceuticals during the second quarter valued at $213,000. OLD Mission Capital LLC acquired a new position in Telix Pharmaceuticals during the fourth quarter valued at $111,000. Finally, JPMorgan Chase & Co. purchased a new stake in Telix Pharmaceuticals in the 3rd quarter worth about $243,000.

Telix Pharmaceuticals Stock Performance

NASDAQ TLX opened at $7.87 on Thursday. Telix Pharmaceuticals has a 1 year low of $6.28 and a 1 year high of $20.00. The business’s fifty day moving average is $7.32 and its two-hundred day moving average is $8.76. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Telix Pharmaceuticals (NASDAQ:TLX) last released its quarterly earnings data on Friday, February 20th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.06). On average, analysts forecast that Telix Pharmaceuticals will post 0.24 EPS for the current fiscal year.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.